Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 56 articles: HTML format

Single Articles

April 2024
1. PASSARO A, Peters S
   Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
   N Engl J Med. 2024;390:1325-1327.
   PubMed    
   
   
   
2. WU YL, Dziadziuszko R, Ahn JS, Barlesi F, et al
   Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
   N Engl J Med. 2024;390:1265-1276.
   PubMed     Abstract available
   
   
   
3. IZZEDINE H, Bouderlique E, Besse B
   Selpercatinib and Pseudo-Decreases in Kidney Function.
   N Engl J Med. 2024;390:1241-1243.
   PubMed    
   
   
   February 2024
4. ZHOU C, Agrawal T, Girard N
   VTE with Amivantamab plus Chemotherapy in NSCLC. Reply.
   N Engl J Med. 2024;390:579-580.
   PubMed    
   
   
   
5. MOIK F, Riedl JM, Ay C
   VTE with Amivantamab plus Chemotherapy in NSCLC.
   N Engl J Med. 2024;390:578-579.
   PubMed    
   
   
   
6. PLANCHARD D, Janne PA, Kobayashi K
   Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
   N Engl J Med. 2024;390:478-479.
   PubMed    
   
   
   
7. VAN WAALWIJK VAN DOORN-KHOSROV, Badrising SK, Burgers S
   Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
   N Engl J Med. 2024;390:478.
   PubMed    
   
   
   January 2024
8. HEYMACH JV, Harpole D, Reck M
   Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
   N Engl J Med. 2024;390:287-288.
   PubMed    
   
   
   
9. HORITA N, Fujiwara Y
   Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
   N Engl J Med. 2024;390:287.
   PubMed    
   
   
   
10. DRILON A, Camidge DR, Lin JJ, Kim SW, et al
    Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:118-131.
    PubMed     Abstract available
    
    
    November 2023
11. ZHOU C, Tang KJ, Cho BC, Liu B, et al
    Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
    N Engl J Med. 2023;389:2039-2051.
    PubMed     Abstract available
    
    
    
12. PLANCHARD D, Janne PA, Cheng Y, Yang JC, et al
    Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2023;389:1935-1948.
    PubMed     Abstract available
    
    
    
13. MULLIGAN L
    Selective RET Kinase Inhibitors and Lung Cancer.
    N Engl J Med. 2023;389:1913-1916.
    PubMed    
    
    
    
14. MCCANNON JB, Shepard JO, Wong AK, Thomas MF, et al
    Case 35-2023: A 38-Year-Old Woman with Waxing and Waning Pulmonary Nodules.
    N Engl J Med. 2023;389:1902-1911.
    PubMed    
    
    
    
15. ZHOU C, Solomon B, Loong HH, Park K, et al
    First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
    N Engl J Med. 2023;389:1839-1850.
    PubMed     Abstract available
    
    
    
16. WU YL, Zhou Q
    Combination Therapy for EGFR-Mutated Lung Cancer.
    N Engl J Med. 2023 Nov 8. doi: 10.1056/NEJMe2311559.
    PubMed    
    
    
    October 2023
17. HEYMACH JV, Harpole D, Mitsudomi T, Taube JM, et al
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 23. doi: 10.1056/NEJMoa2304875.
    PubMed     Abstract available
    
    
    
18. AHN MJ, Cho BC, Felip E, Korantzis I, et al
    Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 20. doi: 10.1056/NEJMoa2307980.
    PubMed     Abstract available
    
    
    
19. PROVENCIO M, Massuti B, Romero A
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2023;389:1534-1535.
    PubMed    
    
    
    
20. VERMA S, Vincent M, Breadner D
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023;389:1534.
    PubMed    
    
    
    
21. TSUBOI M, Herbst RS, Wu YL
    Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
    N Engl J Med. 2023;389:1342.
    PubMed    
    
    
    
22. DI MAIO M
    Osimertinib in Resected EGFR-Mutated NSCLC.
    N Engl J Med. 2023;389:1341-1342.
    PubMed    
    
    
    August 2023
23. SACHER A, LoRusso P, Patel MR, Miller WH Jr, et al
    Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
    N Engl J Med. 2023;389:710-721.
    PubMed     Abstract available
    
    
    
24. LOVLY CM
    Perioperative Immunotherapy - A KEY toward Improved Outcomes for Early-Stage Lung Cancer?
    N Engl J Med. 2023;389:560-561.
    PubMed    
    
    
    June 2023
25. PROVENCIO M, Nadal E, Gonzalez-Larriba JL, Martinez-Marti A, et al
    Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023 Jun 28. doi: 10.1056/NEJMoa2215530.
    PubMed     Abstract available
    
    
    
26. TSUBOI M, Herbst RS, John T, Kato T, et al
    Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
    N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304594.
    PubMed     Abstract available
    
    
    
27. WAKELEE H, Liberman M, Kato T, Tsuboi M, et al
    Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023 Jun 3. doi: 10.1056/NEJMoa2302983.
    PubMed     Abstract available
    
    
    
28. BALDESSARI EM, Mesquida SM
    Phantom Tumor of the Lung.
    N Engl J Med. 2023;388:2086.
    PubMed    
    
    
    April 2023
29. ALTORKI N, Wang X, Stinchcombe TE
    Extent of Surgery for Stage IA Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2023;388:1629-1630.
    PubMed    
    
    
    
30. LI WWL, van der Heide SM, Verhagen AFTM
    Extent of Surgery for Stage IA Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023;388:1629.
    PubMed    
    
    
    February 2023
31. RUSCH VW
    Initiating the Era of "Precision" Lung Cancer Surgery.
    N Engl J Med. 2023;388:557-558.
    PubMed    
    
    
    
32. ALTORKI N, Wang X, Kozono D, Watt C, et al
    Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023;388:489-498.
    PubMed     Abstract available
    
    
    December 2022
33. STRICKLER JH, Satake H, George TJ, Yaeger R, et al
    Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.
    N Engl J Med. 2022 Dec 21. doi: 10.1056/NEJMoa2208470.
    PubMed     Abstract available
    
    
    
34. ROBERTS MB, Lee J, Murphy MC, Kim AY, et al
    Case 37-2022: A 55-Year-Old Man with Fatigue, Weight Loss, and Pulmonary Nodules.
    N Engl J Med. 2022;387:2172-2183.
    PubMed    
    
    
    November 2022
35. TEMEL JS, Dudzinski DM, Digumarthy SR, Keyes CM, et al
    Case 35-2022: A 60-Year-Old Man with Progressive Dyspnea, Neck Swelling, and a Lung Mass.
    N Engl J Med. 2022;387:1889-1896.
    PubMed    
    
    
    September 2022
36. JANNE PA, Sabari JK, Spira AI
    Adagrasib in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2022;387:1238-1239.
    PubMed    
    
    
    
37. KOTECHA R, Sahgal A, Mehta MP
    Adagrasib in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2022;387:1238-1239.
    PubMed    
    
    
    August 2022
38. FORDE PM, Spicer J, Girard N
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.
    N Engl J Med. 2022;387:572-573.
    PubMed    
    
    
    
39. CAO C
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2022;387:571-572.
    PubMed    
    
    
    
40. TANVETYANON T
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2022;387:571.
    PubMed    
    
    
    July 2022
41. BOYCE M, Flower C
    Tripe Palms.
    N Engl J Med. 2022;387:355.
    PubMed    
    
    
    
42. RESTREPO D, Haramati A, McCluskey SM, Branda JA, et al
    Case 22-2022: A 34-Year-Old Woman with Cavitary Lung Lesions.
    N Engl J Med. 2022;387:261-269.
    PubMed    
    
    
    
43. PASSARO A, Peters S
    Setting the Benchmark for KRAS(G12C) -Mutated NSCLC.
    N Engl J Med. 2022;387:180-183.
    PubMed    
    
    
    June 2022
44. JANNE PA, Riely GJ, Gadgeel SM, Heist RS, et al
    Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation.
    N Engl J Med. 2022 Jun 3. doi: 10.1056/NEJMoa2204619.
    PubMed     Abstract available
    
    
    May 2022
45. LI BT, Smit EF, Janne PA
    Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2022;386:1770-1771.
    PubMed    
    
    
    
46. TJONG MC, Mak RH, Louie AV
    Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2022;386:1770.
    PubMed    
    
    
    
47. VIRAY H, Rangachari D, Costa DB
    Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2022;386:1769-1770.
    PubMed    
    
    
    April 2022
48. FORDE PM, Spicer J, Lu S, Provencio M, et al
    Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    N Engl J Med. 2022 Apr 11. doi: 10.1056/NEJMoa2202170.
    PubMed     Abstract available
    
    
    
49. LOVLY CM
    Expanding Horizons for Treatment of Early-Stage Lung Cancer.
    N Engl J Med. 2022 Apr 11. doi: 10.1056/NEJMe2203330.
    PubMed    
    
    
    February 2022
50. WING JR, Kimball A, Rengarajan M
    Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.
    N Engl J Med. 2022;386:781-787.
    PubMed    
    
    
    January 2022
51. PASSARO A, Peters S
    Targeting HER2-Mutant NSCLC - The Light Is On.
    N Engl J Med. 2022;386:286-289.
    PubMed    
    
    
    
52. HORN DM, Haas JS
    Expanded Lung and Colorectal Cancer Screening - Ensuring Equity and Safety under New Guidelines.
    N Engl J Med. 2022 Jan 8. doi: 10.1056/NEJMp2113332.
    PubMed    
    
    
    September 2021
53. JANES SM, Alrifai D, Fennell DA
    Perspectives on the Treatment of Malignant Pleural Mesothelioma.
    N Engl J Med. 2021;385:1207-1218.
    PubMed    
    
    
    
54. LI BT, Smit EF, Goto Y, Nakagawa K, et al
    Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2021 Sep 18. doi: 10.1056/NEJMoa2112431.
    PubMed     Abstract available
    
    
    June 2021
55. AWAD MM, Liu S, Rybkin II, Arbour KC, et al
    Acquired Resistance to KRAS(G12C) Inhibition in Cancer.
    N Engl J Med. 2021;384:2382-2393.
    PubMed     Abstract available
    
    
    
56. SKOULIDIS F, Li BT, Dy GK, Price TJ, et al
    Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
    N Engl J Med. 2021;384:2371-2381.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.